Assessment of FIBROSpect II to Detect Hepatic Fibrosis in Chronic Hepatitis C Patients Atif Zaman, MD, MPH, Hugo R. Rosen, MD, Ken Ingram, PA-C, Christopher L. Corless, MD, PhD, Esther Oh, Katie Smith The American Journal of Medicine Volume 120, Issue 3, Pages 280.e9-280.e14 (March 2007) DOI: 10.1016/j.amjmed.2006.06.044 Copyright © 2007 Elsevier Inc. Terms and Conditions
Figure 1 Performance characteristics of the cohort in terms of negative predictive value (NPV), positive predictive value (PPV) based on the prevalence of significant fibrosis (F2-F4). The American Journal of Medicine 2007 120, 280.e9-280.e14DOI: (10.1016/j.amjmed.2006.06.044) Copyright © 2007 Elsevier Inc. Terms and Conditions
Figure 2 Receiver Operator Characteristic Curve of the FIBROSpect II Index for differentiating Metavir Stage F0-F1 from F2-F4. The American Journal of Medicine 2007 120, 280.e9-280.e14DOI: (10.1016/j.amjmed.2006.06.044) Copyright © 2007 Elsevier Inc. Terms and Conditions
Figure 3 The frequency of Metavir fibrosis stages over the range of FIBROSpect II index scores. The American Journal of Medicine 2007 120, 280.e9-280.e14DOI: (10.1016/j.amjmed.2006.06.044) Copyright © 2007 Elsevier Inc. Terms and Conditions